Warther Private Wealth LLC Sells 500 Shares of AstraZeneca PLC (NASDAQ:AZN)

Warther Private Wealth LLC lowered its position in AstraZeneca PLC (NASDAQ:AZN) by 11.9% in the 3rd quarter, Holdings Channel reports. The fund owned 3,698 shares of the company’s stock after selling 500 shares during the quarter. Warther Private Wealth LLC’s holdings in AstraZeneca were worth $288,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. McClarren Financial Advisors Inc. boosted its stake in AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares in the last quarter. GHP Investment Advisors Inc. bought a new stake in shares of AstraZeneca in the 2nd quarter worth approximately $26,000. Pathway Financial Advisers LLC purchased a new stake in shares of AstraZeneca in the 1st quarter worth approximately $29,000. RFP Financial Group LLC increased its position in AstraZeneca by 56.3% during the 1st quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock valued at $33,000 after buying an additional 178 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its stake in AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after buying an additional 146 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Trading Down 0.2 %

AstraZeneca stock opened at $75.72 on Friday. The firm has a market capitalization of $234.78 billion, a price-to-earnings ratio of 36.67, a P/E/G ratio of 1.43 and a beta of 0.46. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The firm has a 50 day moving average of $80.59 and a 200 day moving average of $78.39. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.99 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.01. The business had revenue of $12.45 billion for the quarter, compared to analysts’ expectations of $12.62 billion. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The business’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period last year, the firm earned $1.08 earnings per share. As a group, research analysts predict that AstraZeneca PLC will post 4.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

AZN has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. TD Cowen lifted their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.